A Phase 1 interventional study of DWP712 and BOTOX® in Glabellar Lines, sponsored by Daewoong Pharmaceutical Co. LTD.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-04.
Sponsored by Daewoong Pharmaceutical Co. LTD. · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To evaluate the safety of 12-week administration of DWP712 inj. in subjects with moderate to severe glabellar lines.
Daewoong Pharmaceutical Co. LTD. is the lead sponsor of 200 studies on the registry; 33 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
-
Patients were intramuscularly injected (IM) with a total of 20U of DWP712 in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
Biological: DWP712
Patients were intramuscularly injected (IM) with a total of 20U of BOTOX® in 5 places of 0.1 mL (4 U/0.1 mL) each on the glabellar line.
Biological: BOTOX®
Clostridium botulinum Toxin
Clostridium botulinum Toxin
Number of occurrences for grade 3 or higher adverse drug reactions (ADRs) according to CTCAE 5.0
Time frame: At 4, 8, 12 week after the injection
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2023 to primary completion in Feb 2024, 2 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Daewoong Pharmaceutical Co. LTD. →